A Japanese life sciences company has moved forward with clinical testing of its proprietary stem cell-derived diabetes therapy, according to industry reports. The advancement positions the firm within Japan’s expanding biotechnology investment landscape, where institutional capital increasingly targets regenerative medicine ventures.
Source: Nikkei Asia Read Full Story